Published in Klin Wochenschr on February 01, 1969
Recurrent purpura due to alcohol-related Schamberg's disease and its association with serum immunoglobulins: a longitudinal observation of a heavy drinker. J Med Case Rep (2016) 1.39
Variations of immunoglobulins in disease. J Clin Pathol Suppl (Assoc Clin Pathol) (1975) 0.76
[Investigations of the T and B cells and the hemopexin-carrying lymphocytes in cases of porphyria cutanea tarda (author's transl)]. Arch Dermatol Res (1976) 0.75
A study on the relationship of porphyria cutanea tarda and liver damage. Arch Dermatol Forsch (1973) 0.75
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol (2009) 1.78
Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol (1991) 1.76
Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol (1987) 1.56
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
CYFRA 21-1. A new marker in lung cancer. Cancer (1993) 1.42
Performance of various mathematical methods for computer-aided processing of radioimmunoassay results. Clin Chim Acta (1978) 1.40
Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol (1997) 1.33
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res (2001) 1.33
Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases. Gastroenterology (1983) 1.26
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie (2003) 1.17
[A kinetic method for determination of the activity of pseudocholinesterase (acylcholine acyl-hydrolase 3.1.1.8.)]. Klin Wochenschr (1967) 1.16
Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol (1996) 1.14
High-dose intravenous gammaglobulin for myasthenia gravis. Lancet (1984) 1.14
Diagnosis of porphyrias by ion-pair high-performance liquid chromatography. J Chromatogr (1980) 1.12
Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology (1991) 1.10
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer (2002) 1.08
[Computer-assisted findings on protein electrophoresis on cellulose acetate film]. J Clin Chem Clin Biochem (1984) 1.07
Circulating lipid A antibodies despite absence of systemic endotoxemia in patients with Crohn's disease. Dig Dis Sci (1984) 1.04
[On an apparatus for the safe and controlable filling of the abdominal cavity with gas for laparoscopy]. Klin Wochenschr (1966) 1.02
Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol. Clin Chim Acta (1990) 1.01
[Determination of creatine kinase-MB in serum using inhibiting antibodies (author's transl)]. Klin Wochenschr (1976) 1.00
Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem (1993) 0.99
Determination of creatine kinase isoenzyme MB activity in serum using immunological inhibition of creatine kinase M subunit activity. Activity kinetics and diagnostic significance in myocardial infarction. Clin Chim Acta (1976) 0.96
Hemostatic variables and blood loss during orthotopic human liver transplantation. Transplant Proc (1991) 0.95
Identification of membrane antigens in granulocytes and colonic carcinoma cells by a monoclonal antibody specific for biliary glycoprotein, a member of the carcinoembryonic antigen family. Cancer Lett (1991) 0.95
MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol (1997) 0.94
Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res (1997) 0.94
Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis. Hepatology (1988) 0.93
Elevated serum CA 125 levels in patients with benign ascitic or pleural effusions. Tumour Biol (1988) 0.93
Measurement of proteins with the Behring Nephelometer. A multicentre evaluation. J Clin Chem Clin Biochem (1989) 0.92
Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma. Eur J Clin Chem Clin Biochem (1992) 0.92
Serum marker combinations in human breast cancer (review). In Vivo (1994) 0.92
Epidermal growth factor receptors and epidermal growth factor-like activity in colorectal mucosa, adenomas and carcinomas. Klin Wochenschr (1989) 0.91
[Isolation of immunologically active gamma-globulins of a horse-anti-dog lymphocyte serum]. Klin Wochenschr (1967) 0.91
Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry (1985) 0.90
Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res (1997) 0.90
Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res (1995) 0.89
Immune response of peripheral blood mononuclear cells to HBx-antigen of hepatitis B virus. Hepatology (1991) 0.89
Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol (1982) 0.89
Analytical performance of the random access analyser Hitachi 737. A multicentre evaluation. J Clin Chem Clin Biochem (1986) 0.88
Diagnostic accuracy of CT in circumscript liver disease. AJR Am J Roentgenol (1978) 0.88
Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci (2013) 0.88
Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer (1995) 0.88
Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol (1988) 0.87
From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev (1992) 0.87
[Infiltration patterns of plasmacytomas in magnetic resonance tomography]. Rofo (1996) 0.86
[Paramyloidosis, macroglossia and Raynaud's syndrome in Bence-Jones plasmacytoma]. Dtsch Med Wochenschr (1971) 0.86
Significance of CEA determinations in patients with cancer of the colon-rectum and the mammary gland in comparison to physiological states in connection with pregnancy. Bull Cancer (1977) 0.86
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem (1994) 0.86
Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol (1995) 0.86
Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer. Oncodev Biol Med (1980) 0.85
Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res (1996) 0.85
Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience. Cancer (1996) 0.85
T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation. J Hepatol (1992) 0.85
[Immunogenetics of myasthenia gravis. Significance of HLA-, complement and Cm gene systems for clinical and immunologic parameters]. Dtsch Med Wochenschr (1983) 0.84
[Serum bilirubin determination in newborn infants. A new micromethod for the determination of serum of plasma bilirubin in newborn infants]. Fortschr Med (1975) 0.84
Sclerotherapy of a bleeding duodenal varix. Endoscopy (1982) 0.84
Hepatotoxicity following desflurane anesthesia. Hepatology (1999) 0.84
Bone marrow histology in Waldenström's macroglobulinaemia. Clinical relevance of subtype recognition. Scand J Haematol (1983) 0.84
Assessment of bone marrow histology in the malignant lymphomas (non-Hodgkin's): correlation with clinical factors for diagnosis, prognosis, classification and staging. Br J Haematol (1982) 0.84
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem (1993) 0.84
Ferritin in cerebrospinal fluid differentiation between central nervous system haemorrhage and traumatic spinal puncture. J Clin Pathol (1988) 0.83
Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases. Lung (1994) 0.83
Risk of virus transmission by jet injection. Lancet (1988) 0.83
Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671. Neurology (1991) 0.82
Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. J Neurol Neurosurg Psychiatry (1980) 0.82
In vitro studies on the mechanism of hyperacute xenograft rejection. Transplant Proc (1971) 0.82
Computerized tomography and nuclear imaging of the liver: a comparative study in 83 cases. Eur J Nucl Med (1978) 0.82
Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis. Anticancer Res (1999) 0.82
Production of interferon alpha and interferon gamma by peripheral blood leukocytes from patients with chronic hepatitis B virus infection. J Med Virol (1985) 0.81
[Immunglobulins G, A, M, and E in lymphogranulomatosis (author's transl)]. MMW Munch Med Wochenschr (1976) 0.81
CA125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res (1997) 0.81
[Ethanol influence on purine catabolism of human liver]. Verh Dtsch Ges Inn Med (1973) 0.81
[Serum immunoglobulin concentrations in Crohn's disease. Clinical relevance and comparison with lipid-A-antibody titers (author's transl)]. Z Gastroenterol (1981) 0.81
Beta- and gamma-interferon in chronic active hepatitis B. A pilot trial of short-term combination therapy. Gastroenterology (1989) 0.81
Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer (1991) 0.81
Interferon alpha in hepatitis type B and non-A, non-B. Defective production by peripheral blood mononuclear cells in chronic infection and development of serum interferon in acute disease. J Hepatol (1988) 0.81
[The significance of determining antibodies to acetylcholine receptor in myasthenia gravis (author's transl)]. Klin Wochenschr (1979) 0.80
Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol (1984) 0.80
Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy. Gynecol Oncol (1990) 0.80
[The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome]. Fortschr Med (1978) 0.80
Quantitative determination of creatine kinase isoenzyme catalytic concentrations in serum using immunological methods. J Clin Chem Clin Biochem (1977) 0.80
Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer (1993) 0.80
Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma. J Thorac Cardiovasc Surg (1990) 0.79
Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin. Am J Clin Pathol (1996) 0.79
Low serum C4 concentrations and peripheral neuropathy in type I and type II diabetes. Br Med J (Clin Res Ed) (1986) 0.79
Cytolytic T cell clones derived from liver tissue of patients with chronic hepatitis B. Eur J Immunol (1986) 0.79
Bone marrow histology and serum beta 2 microglobulin in multiple myeloma--a new prognostic strategy. Eur J Haematol Suppl (1989) 0.79
Value of HAMA--determination in clinical practice--an overview. Anticancer Res (1997) 0.79
[Studies on the metabolism of testosterone and delta-4-androstendione in the human liver]. Klin Wochenschr (1971) 0.79
Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Anticancer Res (1997) 0.79